@FiercePharma: Still trending on our website (in a big way): Teva profile as No. 1 on our Top 10 Generics Makers list. Profile | Follow @FiercePharma
@EricPFierce: What drugs are up for grabs by generic makers next year? Here's the FiercePharma list of 2014 patent losses. Report | Follow @EricPFierce
@CarlyHFierce: Biogen's Tecfidera drives rosy Q3 results, higher forecast. More | Follow @CarlyHFierce
> India's Sun Pharmaceutical saw shares fall after Bloomberg reported FDA worries about quality at its U.S. subsidiary Caraco. Report
> Germany's Stada signed on with Apotex to market a biosimilar version of Amgen's ($AMGN) Neupogen in Europe; the knockoff version will be sold under the brand name Grastofil. Report
> Lundbeck won FDA approval to market its seizure drug Sabril for use in children 10 years of age and older. Report
> The FDA's decision to tighten restrictions on painkiller prescribing has been coming for many years. Report (sub. req.)
> When the FDA approved Zogenix's ($ZGNX) new painkiller Zohydro last week, it did not require the drug to have built-in mechanisms to deter abuse. Report
@FierceMedDev: Abbott's MitraClip heart valve device gains FDA's long-awaited blessing. ICYMI Friday | Follow @FierceMedDev
@MarkHFierce: GE healthcare is aiming for a 2014 launch for its new Alzheimer's imaging agent. More from FierceDiagnostics | Follow @MarkHFierce
@MichaelGFierce: A blog post from the FDA late last week highlighted the agency's efforts to regulate nanotechnology. Blog | Follow @MichaelGFierce
> Boston Scientific bags CE mark for heart valve as market crowds. News
> Bill would clarify FDA oversight over mobile medical apps. Story
> Edwards joins Middle Peak financing to gain stake in mitral device race. More
Biotech News
@FierceBiotech: CytomX 'probody' kills pancreatic cancer cells, leaves healthy tissue intact. Story from FierceBiotech Research | Follow @FierceBiotech
@JohnCFierce: UPDATED: FDA overrides Zohydro panel, approves pure hydrocodone pain med. Story | Follow @JohnCFierce
@DamianFierce: ICYMI: Aerie prices $67M IPO and becomes 40th biotech to go public this year. Story | Follow @DamianFierce
@EmilyMFierce: GMOs Versus Overuse Of Antibiotics: Which Is The Greater Evil? More from Forbes | Follow @EmilyMFierce
> Bristol-Myers takes shot at Humira as arthritis drug aces Phase IIb. Story
> Bullish Actelion once again heats up as a possible takeover target. Item
> Bristol-Myers adds promising survival update on breakthrough cancer drug. Report
> Gilead sweeps FDA panel vote for pioneering hep C drug sofosbuvir. Article
CRO News
> InVentiv opens U.K. hub as EU demand climbs. More
> Dendreon picks CMO PharmaCell to make Provenge in Europe. Item
> Novum reaches into N. Dakota for clinical trials. Article
> SRI sets sights on CRO growth with Virginia expansion. Story
> Icon boosts outlook after 19% sales jump. Report
> CRO Atheris hooks up with Debiopharm for cancer R&D. More
Biotech IT News
> Medidata eyes Novartis' business after inking Alcon deal. More
> Broad Institute to offer sequencing services after receiving CLIA nod. Item
> VCs tap Amgen-acquired genomics database to power startup. Report
> Oxford Nanopore readying for user tests of handheld sequencing device. Story
> Amazon, Baylor and DNAnexus team up for huge sequencing project. Article
And Finally... On the latest list of India's super-rich, the pharma business accounted for 11% of the entries. Report